Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
81
PharmaCompass offers a list of Deucravacitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deucravacitinib manufacturer or Deucravacitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deucravacitinib manufacturer or Deucravacitinib supplier.
PharmaCompass also assists you with knowing the Deucravacitinib API Price utilized in the formulation of products. Deucravacitinib API Price is not always fixed or binding as the Deucravacitinib Price is obtained through a variety of data sources. The Deucravacitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deucravacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deucravacitinib, including repackagers and relabelers. The FDA regulates Deucravacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deucravacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deucravacitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deucravacitinib supplier is an individual or a company that provides Deucravacitinib active pharmaceutical ingredient (API) or Deucravacitinib finished formulations upon request. The Deucravacitinib suppliers may include Deucravacitinib API manufacturers, exporters, distributors and traders.
click here to find a list of Deucravacitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Deucravacitinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Deucravacitinib active pharmaceutical ingredient (API) in detail. Different forms of Deucravacitinib DMFs exist exist since differing nations have different regulations, such as Deucravacitinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Deucravacitinib DMF submitted to regulatory agencies in the US is known as a USDMF. Deucravacitinib USDMF includes data on Deucravacitinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Deucravacitinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Deucravacitinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Deucravacitinib Drug Master File in Korea (Deucravacitinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Deucravacitinib. The MFDS reviews the Deucravacitinib KDMF as part of the drug registration process and uses the information provided in the Deucravacitinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Deucravacitinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Deucravacitinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Deucravacitinib suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deucravacitinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deucravacitinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deucravacitinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deucravacitinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deucravacitinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deucravacitinib suppliers with NDC on PharmaCompass.
Deucravacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deucravacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deucravacitinib GMP manufacturer or Deucravacitinib GMP API supplier for your needs.
A Deucravacitinib CoA (Certificate of Analysis) is a formal document that attests to Deucravacitinib's compliance with Deucravacitinib specifications and serves as a tool for batch-level quality control.
Deucravacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Deucravacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deucravacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Deucravacitinib EP), Deucravacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deucravacitinib USP).
